Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 10/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 10/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590759 | 0.94 | AKR1C3 (0.35) | AKR1C3AKR1C2PTGER4PTGS1PTGS2 | |
| SCHEMBL2298376 | 0.93 | PTGER4 (0.44) | AKR1C3AKR1C2PTGER4PTGS1PTGS2 | |
| SCHEMBL1590458 | 0.87 | PTGER4 (0.40) | AKR1C3AKR1C2PTGER4PTGS1PTGS2 | |
| SCHEMBL1591302 | 0.87 | PTGER4 (0.41) | AKR1C3AKR1C2PTGER4PTGS1PTGS2 | |
| SCHEMBL2302719 | 0.87 | AKR1C3 (0.39) | AKR1C3AKR1C2PTGER4PTGS1PTGS2 | |
| SCHEMBL1590906 | 0.85 | PTGER4 (0.33) | AKR1C3AKR1C2PTGER4PTGS1HTR1A | |
| SCHEMBL1590901 | 0.85 | PTGER4 (0.35) | AKR1C3AKR1C2PTGER4PTGS1HTR1A | |
| SCHEMBL2299042 | 0.85 | AKR1C3 (0.43) | AKR1C3AKR1C2PTGER4PTGS1HTR1A | |
| SCHEMBL1590787 | 0.84 | AKR1C3 (0.36) | AKR1C3AKR1C2PTGER4PTGS1PTGS2 | |
| SCHEMBL1590112 | 0.84 | AKR1C3 (0.36) | AKR1C3AKR1C2PTGER4PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER1, PTGER2 | AKR1C3 411/4885AKR1C2 598/4885PTGER4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.